Regulation of pancreatic cancer TRAIL resistance by protein O-GlcNAcylation

TRAIL-activating therapy is promising in treating various cancers, including pancreatic cancer, a highly malignant neoplasm with poor prognosis. However, many pancreatic cancer cells are resistant to TRAIL-induced apoptosis despite their expression of intact death receptors (DRs). Protein O-GlcNAcyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shan-zhong, Xu, Fei, Yuan, Kaiyu, Sun, Yong, Zhou, Tong, Zhao, Xinyang, McDonald, Jay M, Chen, Yabing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183418/
https://www.ncbi.nlm.nih.gov/pubmed/31896813
http://dx.doi.org/10.1038/s41374-019-0365-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183418/
https://www.ncbi.nlm.nih.gov/pubmed/31896813
http://dx.doi.org/10.1038/s41374-019-0365-z

Ejemplares similares